Dr Paula Cunnea is an Advanced Research Fellow based in the Ovarian Cancer Action Research Centre, in the Division of Cancer. Paula leads a research group with Professor Christina Fotopoulou, focused on investigating tumour heterogeneity in high grade serous ovarian cancer, developing different 3D models of ovarian cancer, and applying different bioengineering approaches to cancer research. Paula runs multidisciplinary projects in the area of chemotherapy resistance in ovarian cancer and development of novel therapeutics to target this resistance.
Paula joined the Ovarian Cancer Action Research centre in 2012, and initially worked on a collaborative FP7 European Union funded project (Ovarian Cancer Therapy – Innovative Models Prolong Survival, OCTIPS), aiming to identify and characterise the cell population within an ovarian tumour that causes the patient to relapse, and to develop novel therapies in innovative model systems to combat the development of resistance to chemotherapy.
Paula obtained her primary BSc degree in Biomedical Science/Applied Science from Dublin Institute of Technology and Trinity College Dublin, Ireland. Paula achieved her PhD in December 2006 following post-graduate research in the Karolinska Institute, Stockholm, Sweden. Paula worked as a postdoctoral researcher in National University of Ireland Galway and Queen's University Belfast prior to joining Imperial College.
et al., 2023, Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: implications for surgical and clinical outcomes, Cell Reports Medicine, Vol:4, ISSN:2666-3791, Pages:1-20
et al., 2022, Toll-like receptor-targeted anti-tumor therapies: Advances and challenges, Frontiers in Immunology, Vol:13, ISSN:1664-3224, Pages:1-37
et al., 2023, Evaluation of THEO-260 as a novel oncolytic virus therapy for treating stromal rich tumours., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), LIPPINCOTT WILLIAMS & WILKINS, ISSN:0732-183X
et al., 2023, Immune modulation and the oral live biotherapeutic product, MRx0518, in treatment-naive patients with cancer: Updated safety data, Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), LIPPINCOTT WILLIAMS & WILKINS, ISSN:0732-183X
et al., 2022, ORAL ADMINISTRATION OF MRX0518 IN TREATMENTNAIVE CANCER PATIENTS IS ASSOCIATED WITH COMPOSITIONAL TAXONOMIC AND METABOLOMIC CHANGES INDICATIVE OF ANTI-TUMORIGENIC EFFICACY, BMJ PUBLISHING GROUP, Pages:A659-A659